Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regularly issues news on its medicines, clinical programs and corporate developments across multiple therapeutic areas. As a biotechnology company focused on serious diseases, Regeneron’s announcements often cover advances in eye care, allergic and inflammatory diseases, oncology, hematology, cardiovascular disease, infectious disease and rare conditions.
News about Regeneron frequently highlights regulatory milestones for its marketed products. Recent examples include approvals for Dupixent (dupilumab) in additional indications and age groups, such as chronic spontaneous urticaria in the European Union and bronchial asthma in children in Japan, as well as expanded indications and dosing flexibility for EYLEA HD (aflibercept) Injection 8 mg in retinal diseases. The company also reports on new approvals for Libtayo (cemiplimab), including adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation in the European Union.
Investors and healthcare professionals can expect updates on Regeneron’s oncology and hematology pipeline, including data from trials of Lynozyfic (linvoseltamab) in multiple myeloma and odronextamab in B‑cell non‑Hodgkin lymphomas, as well as programs in paroxysmal nocturnal hemoglobinuria and severe aplastic anemia. Regeneron often presents such data at major medical meetings, and issues press releases summarizing efficacy and safety results.
Corporate and R&D collaboration news is another recurring theme. The company has announced partnerships such as its global collaboration with Tessera Therapeutics on TSRA‑196, an investigational in vivo gene editing therapy for alpha‑1 antitrypsin deficiency, and provides updates on its factor XI antibody program for anticoagulation. Regeneron also communicates scheduling of quarterly and annual financial results webcasts and investor events, including its ‘Regeneron Roundtable’ series.
This news page aggregates these types of updates so readers can follow product approvals, late-stage trial readouts, scientific presentations, strategic collaborations and financial reporting dates related to REGN. For ongoing research and investment analysis, checking this feed regularly can provide timely insight into Regeneron’s progress across its broad portfolio.
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced a strategic collaboration with Truveta, Inc. and its U.S. health systems network, investing $119.5 million in Truveta's Series C financing round. The partnership launches the Truveta Genome Project, which aims to sequence up to ten million additional de-identified patient volunteers with linked electronic health records (EHRs).
The project will expand Regeneron Genetics Center's existing database of nearly three million exomes. RGC will conduct exome sequencing, genotyping, and imputation of the volunteers using biospecimens from Truveta's health system members. This data will integrate with Truveta's medical database, which represents over 120 million patients across 30 health systems.
Illumina, Inc. will also invest $20 million in the financing round. RGC will maintain exclusive rights to perform research-related sequencing on collected samples and access de-identified EHR data from study participants. The collaboration aims to accelerate drug target discovery, optimize clinical trials, and advance healthcare delivery.
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced it will release its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time on the same day.
Investors can access the conference call through a webcast on Regeneron's investor relations website. For telephone participation, advance registration is required through a provided link, after which participants will receive confirmation emails with access details. A replay and transcript will be available on the company's website for at least 30 days following the call.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced positive Phase 2 results for two novel monoclonal antibodies, REGN7508 and REGN9933, targeting Factor XI for thrombosis control. The trials demonstrated robust antithrombotic effects with no clinically relevant bleeding observed. REGN7508 showed superiority to enoxaparin and non-inferiority to apixaban, while REGN9933 proved non-inferior to enoxaparin in preventing venous thromboembolism after knee surgery.
Key results showed VTE events in 7% of patients for REGN7508, 17% for REGN9933, compared to 21% for enoxaparin and 12% for apixaban. No major bleeding or serious adverse events were reported across all treatment arms. The company plans to initiate Phase 3 trials in 2025.
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 13, 2025, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). Investors and interested parties can access the webcast through Regeneron's website investor section. A replay and transcript will be available on the company's website for at least 30 days after the presentation.
Regeneron Pharmaceuticals (REGN) announced positive Phase 3 QUASAR trial results for EYLEA HD® (aflibercept) Injection 8 mg in treating macular edema following retinal vein occlusion (RVO). The trial met its primary endpoint, demonstrating that EYLEA HD administered every 8 weeks achieved non-inferior vision gains compared to EYLEA® 2 mg monthly dosing.
Key findings at 36 weeks showed mean vision improvements of 17.0-19.1 letters for EYLEA HD groups versus 17.8 letters for EYLEA. Notably, about 90% of EYLEA HD patients maintained 8-week dosing intervals. The safety profile remained consistent with previous trials. Regeneron plans to submit a supplementary biologics license application to the FDA in Q1 2025.
Regeneron Pharmaceuticals (NASDAQ: REGN) has secured its sixth consecutive position in the Dow Jones Sustainability World Index (DJSI World) and fifth consecutive inclusion in the DJSI North America Index. The company ranks in the top 1% of global biotechnology companies, being one of only six biotech firms globally in the DJSI World Index.
The company's success stems from significant achievements in Societal Healthcare, Human Capital Management, and Corporate Governance. Their responsibility strategy focuses on three key areas: improving lives of people with serious diseases, fostering integrity and excellence, and building sustainable communities. Regeneron is on track to meet its 2025 goals, which include developing ~40 investigational medicines, implementing responsible AI practices, ensuring global pay equity, and enhancing treatment access in lower-income countries.
Regeneron Pharmaceuticals (NASDAQ: REGN) presented new data for odronextamab at the ASH Annual Meeting, highlighting promising results across multiple B-cell lymphoma types. In the OLYMPIA-1 trial's safety lead-in, odronextamab achieved complete responses in all 12 evaluable previously untreated follicular lymphoma patients.
The ELM-1 trial's expansion cohort showed 48% objective response rate in diffuse large B-cell lymphoma patients who progressed after CAR-T therapy, with 32% achieving complete response. The ELM-2 trial demonstrated 77% complete response rate in relapsed/refractory marginal zone lymphoma patients.
Odronextamab is currently approved in the EU as Ordspono™ for certain lymphoma indications, with U.S. regulatory resubmission expected in first half of 2025.
Regeneron Pharmaceuticals announced positive Phase 3 data for their novel combination treatment pozelimab and cemdisiran (poze-cemdi) in treating paroxysmal nocturnal hemoglobinuria (PNH). The exploratory cohort of the ACCESS-1 trial showed superior results compared to standard-of-care ravulizumab.
Key findings showed that 96% of patients achieved adequate LDH control with poze-cemdi, compared to 80% with ravulizumab. Additionally, 93% achieved LDH normalization with poze-cemdi versus 65% with ravulizumab. The treatment demonstrated an 84% decrease in LDH from baseline at week 26.
The safety profile was comparable to approved C5 inhibitors, with treatment-emergent adverse events occurring in 84% of poze-cemdi patients versus 87% for ravulizumab. The combination therapy offers the advantage of four-week subcutaneous delivery with potential for self-administration.
Regeneron Pharmaceuticals will present new data from its hematology pipeline across 23 abstracts at the ASH 2024 Annual Meeting. Key highlights include head-to-head results comparing pozelimab plus cemdisiran versus ravulizumab in paroxysmal nocturnal hemoglobinuria, and initial results for odronextamab in first-line follicular lymphoma. The presentations showcase progress in treating 10 types of blood cancers and disorders through various therapeutic approaches, including CD3 bispecific antibodies, costimulatory bispecific antibodies, and a combination of monoclonal antibody and siRNA. Notable presentations include results from the Phase 3 OLYMPIA-1 trial, ELM-1 and ELM-2 trials in diffuse large B-cell lymphoma, and updates on linvoseltamab in multiple myeloma.
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced its upcoming participation in two major investor conferences. The company will present at the Jefferies London Healthcare Conference on November 19, 2024, at 11:00 a.m. BST (6:00 a.m. ET), and at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024, at 9:30 a.m. ET.
Both presentations will be accessible via webcast through Regeneron's investor relations website. Recordings and transcripts will remain available for a minimum of 30 days after the events.